Decision Aid–Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Qualitative Study
A DA-led strategy for tapering advanced therapy in RA was acceptable to patients and feasible in practice. Sending patients a DA ahead of their appointment facilitated patient-led conversations about tapering.
Authors
- Elżbieta Kamińska
- Claire E.H. Barber (ORCID: https://orcid.org/0000-0002-3062-5488)
- Glen Hazlewood (ORCID: https://orcid.org/0000-0001-7709-3741)
- Dawn P. Richards (ORCID: https://orcid.org/0000-0003-1151-0826)
- Nick Bansback (ORCID: https://orcid.org/0000-0002-1510-3462)
- Laurie Proulx (ORCID: https://orcid.org/0000-0003-1656-0371)
- Michelle Jung (ORCID: https://orcid.org/0009-0004-8560-829X)
- Ann Rebutoc
- Jungyeon Lee
Institutions
- University of British Columbia (CA)
- University of Calgary (CA)
- St. Paul's Hospital (CA)
- Research Canada (CA)
- Alberta Bone and Joint Health Institute (CA)
- Arthritis Research Centre of Canada (CA)
- Canadian Arthritis Patient Alliance (CA)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2024-08-15
- DOI
- https://doi.org/10.3899/jrheum.2024-0383
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Canadian Institutes of Health Research